The rise of highly effective GLP-1 receptor agonists and dual incretin therapies has transformed obesity treatment. Medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are helping patients achieve levels of weight loss that were previously difficult to attain without bariatric surgery. However, as clinicians celebrate these advances, a …
Read More »Can Muscle Quality Predict Diabetes Outcomes Better Than BMI?
For decades, body mass index (BMI) has been the standard tool for assessing metabolic health and diabetes risk. However, many clinicians now question whether weight alone tells the full story. Some people with a “normal” BMI still develop insulin resistance and type 2 diabetes, while others with higher body weight …
Read More »GLP-1 Therapy and Muscle Loss: Are We Overlooking Sarcopenia Risk?
Losing 30 pounds may sound like an undeniable success story. However, what if part of that weight loss comes from muscle instead of fat? As more patients use GLP-1 medications such as semaglutide and tirzepatide, clinicians are starting to ask an important question: are these drugs quietly contributing to the …
Read More »GLP-1s and Lean Mass: Preserving Muscle and Strength During Rapid Weight Loss
The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …
Read More »The Expanding Landscape of Diabetes Complications: Liver Disease, Cancer, and Frailty
Early in training, many clinicians learn the classic “eye–kidney–foot” framework for recognizing and managing complications of diabetes. However, as science advances, the range of recognized consequences of diabetes—and opportunities for earlier intervention—continues to broaden. Today, the concept of diabetes complications screening must evolve to include conditions such as metabolic dysfunction–associated …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.